Status: Not yet recruiting
An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Study GB3226-DEV-001 is a Phase 1/2, open-label, dose-escalation and expansion study of GB3226 in the treatment of relapsed or refractory acute myeloid leukaemia
Participants needed: 184
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Galecto Biotech ABUpdated: Jul 24, 2025
Eligibility criteria
Patients in Phase 1 must have active acute myeloid leukemia (bone marrow blasts... [+18]
Diagnosis of active acute promyelocytic leukemia. (APML) [+25]